CMV IgG Levels and Immunotherapy Outcomes in Melanoma Patients
Author Information
Author(s): Strobel Sophia B., Machiraju Devayani, Wiecken Melanie, Richter Jasmin, Klein Julian A. F., Berger Annemarie, Hassel Jessica C.
Primary Institution: Medical Faculty Heidelberg, Heidelberg University, Germany
Hypothesis
What is the relationship between CMV IgG levels and outcomes in melanoma patients treated with immunotherapy?
Conclusion
High levels of CMV IgG in the blood may indicate poor outcomes in melanoma patients receiving immunotherapy.
Supporting Evidence
- Patients with high CMV IgG titers were more likely to experience disease progression.
- High CMV IgG levels correlated with reduced immune cell counts in the blood.
- ICI-induced hepatitis was not associated with CMV IgG or IgM levels.
Takeaway
This study found that high CMV IgG levels in melanoma patients treated with immunotherapy could mean they might not do as well.
Methodology
The study analyzed CMV IgG and IgM levels in blood samples from melanoma patients receiving immunotherapy and assessed their relationship with treatment outcomes.
Potential Biases
Potential biases due to the retrospective nature of the study and the reliance on medical records.
Limitations
The study is retrospective and limited by the availability of biomaterial and different methods used for CMV testing.
Participant Demographics
Median age of participants was 64 years, with 57% being men.
Statistical Information
P-Value
p=0.047
Confidence Interval
95% CI: 5–9 months for PFS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website